Prognostic Value of YKL-40 in Patients with Glioblastoma: a Systematic Review and Meta-analysis

Biomarkers of glioblastoma multiforme

(2015) Stylianos Nicolaidis   METABOLISM-CLINICAL AND EXPERIMENTAL

Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

(2014) Jayson I. L. Bastien et al.   CANCER

Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma

(2014) Jaime Gállego Pérez-Larraya et al.   CANCER

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

(2014) Jeffrey J. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

Emerging Therapies for Glioblastoma

(2014) Alissa A. Thomas et al.   JAMA Neurology

Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis

(2014) Vladimir Riabov et al.   Frontiers in Physiology

Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank

(2014) Andrea V Margulis et al.   Clinical Epidemiology

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

(2014) Mira Patel et al.   Cancers

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma

(2014) Fabio M. Iwamoto et al.   Frontiers in Oncology

Diverse pathological implications of YKL-40: Answers may lie in ‘outside-in’ signaling

(2013) Mansi Prakash et al.   CELLULAR SIGNALLING

Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients

(2012) Maurizio Salvati et al.   JOURNAL OF NEUROSURGERY

Astrocyte and Macrophage Regulation of YKL-40 Expression and Cellular Response in Neuroinflammation

(2011) Dafna Bonneh-Barkay et al.   BRAIN PATHOLOGY

Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

(2011) Jens Kastrup   IMMUNOBIOLOGY

Serum YKL-40 following resection for cerebral glioblastoma

(2011) Daniela Bernardi et al.   JOURNAL OF NEURO-ONCOLOGY

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas

(2011) F. M. Iwamoto et al.   NEURO-ONCOLOGY

CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells

(2010) Bo Mi Ku et al.   INTERNATIONAL JOURNAL OF CANCER

In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases

(2010) Dafna Bonneh-Barkay et al.   Journal of Neuroinflammation

Plasma YKL-40: a potential new cancer biomarker?

(2009) Julia S Johansen et al.   Future Oncology